Study compares empiric oral antibiotic regimens for community-acquired pneumonia :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Which oral antibiotics work best for mild-to-moderate community-acquired pneumonia?

Community-acquired pneumonia Community-acquired pneumonia
Community-acquired pneumonia Community-acquired pneumonia

What's new?

Quinolones show the strongest trends for better clinical response and lower mortality in adults with mild-to-moderate community-acquired pneumonia, though no antibiotic proves clearly superior.

A network meta-analysis has examined how different empiric oral antibiotic regimens perform in adults with mild-to-moderate community-acquired pneumonia (CAP), highlighting differences in clinical response and mortality but stopping short of identifying a clearly superior option. Researchers systematically reviewed PubMed, the Cochrane Library, and reference lists of clinical guidelines and prior systematic reviews to identify randomized trials involving adults with radiologically confirmed mild-to-moderate CAP.

Eligible studies included those who received initial oral antibiotic therapy and reported outcomes on clinical cure or mortality. Data were abstracted in parallel, and both antibiotic-specific and class-based analyses were performed. Results were displayed via network diagrams and forest plots, with rankings assessed by p-scores. Research quality was evaluated via the Cochrane Risk of Bias framework, alongside assessments of both local and global inconsistency. The review included 24 randomized trials involving 9,361 patients. Of these, 6 were deemed low risk of bias, 6 unclear, and 12 high risk.

Key findings

1. Clinical response

  • Nemonoxacin, levofloxacin, and telithromycin ranked highest for attaining a clinical response (p-scores 0.79, 0.71, and 0.69, respectively).
  • Amoxicillin and penicillin were least likely to yield a clinical cure

2. Mortality outcomes

  • Levofloxacin, amoxicillin-clavulanate, azithromycin, and nemonoxacin were most strongly linked with reduced mortality (p-scores 0.85, 0.75, 0.74, and 0.68, respectively).

3. By antibiotic class

  • Quinolones and macrolides performed best for clinical response (p-scores 0.71 and 0.70).
  • Beta-lactams and combinations of amoxicillin-clavulanate with macrolides ranked lower (p-scores 0.22 and 0.11).
  • Quinolones also appeared most beneficial in reducing mortality (p-score 0.63).

Despite these trends, the authors noted that the confidence intervals were wide and overlapping, limiting certainty about any one regimen’s superiority. To sum up, quinolones may yield advantages in both clinical cure rates and mortality outcomes for empiric treatment of mild-to-moderate CAP. However, no antibiotic emerged as definitively more beneficial than the rest. The authors emphasize the requisition for further large-scale, high-quality trials to guide evidence-based recommendations in outpatient pneumonia care.

Source:

Journal of General Internal Medicine

Article:

Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis

Authors:

Peter K Kurotschka et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: